Showing results (201-210 of 293) with videos related to

Sort By:
Pageof 30
The Journal of Prevention of Alzheimer'S Disease|October 24, 2023
Initial Experiences with Amyloid-Related Imaging Abnormalities in Patients Receiving Aducanumab Following Accelerated ApprovalM D Howe, K J Britton, H E Joyce, et al.
Proceedings of the National Academy of Sciences of the United States of America|August 23, 2019
The RNA demethylase FTO is required for maintenance of bone mass and functions to protect osteoblasts from genotoxic damageQian Zhang, Ryan C Riddle, Qian Yang, et al.
Diabetes Care|August 23, 2014
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forumWilliam T Cefalu, John B Buse, Stefano Del Prato, et al.
Molecular and Cellular Biology|March 25, 2015
Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblastJulie L Frey, Zhu Li, Jessica M Ellis, et al.
Cardiovascular Diabetology|September 26, 2021
Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWINDManige Konig, Matthew C Riddle, Helen M Colhoun, et al.
Diabetes Care|November 1, 2019
<i>Diabetes Care</i> Editors' Expert Forum 2018: Managing Big Data for Diabetes Research and CareMatthew C Riddle, Lawrence Blonde, Hertzel C Gerstein, et al.
Iscience|August 3, 2023
Peroxisome proliferator activated receptor-γ in osteoblasts controls bone formation and fat mass by regulating sclerostin expressionSoohyun P Kim, Avery H Seward, Jean Garcia-Diaz, et al.
The Journal of Biological Chemistry|March 8, 2019
Lrp4 expression by adipocytes and osteoblasts differentially impacts sclerostin's endocrine effects on body composition and glucose metabolismSoohyun P Kim, Hao Da, Zhu Li, et al.
Diabetes Technology & Therapeutics|August 26, 2011
International Forum for the Advancement of Diabetes Research and Care, April 29-30, 2011, Athens, GreeceGeremia B Bolli, Larry C Deeb, Satish K Garg, et al.
Diabetes Technology & Therapeutics|February 4, 2016
Efficacy and Safety of Flexible Versus Fixed Dosing Intervals of Insulin Glargine 300 U/mL in People with Type 2 DiabetesMatthew C Riddle, Geremia B Bolli, Philip D Home, et al.
Pageof 30